返回 
加入收藏
基于美国FAERS数据库的培唑帕尼不良事件信号挖掘与分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 基于美国FAERS数据库的培唑帕尼不良事件信号挖掘与分析 |
| TITLE： | Signals mining and analysis of adverse drug events of pazopanib based on FAERS database |
| 摘要： | 目的 挖掘并分析培唑帕尼上市后的药物不良事件（ADE）信号，为临床安全用药提供参考。方法通过OpenVigil2.1数据平台对美国FDA药物不良事件报告系统（FAERS）数据库进行信号挖掘，收集培唑帕尼2009年10月－2022年6月的ADE报告，采用比例失衡法中的比例报告比值（PRR）法和报告比值比（ROR）法检测该药的ADE信号并进行分析。结果共筛选出以培唑帕尼为首要怀疑药物的ADE报告16655份，经ROR法、PRR法挖掘出ADE信号220个，涉及19个系统器官分类。信号频度排前10位的ADE信号在该药的药品说明书中均有记载；发现了88个新的ADE信号，主要分布在胃肠系统、各种检查、肾脏和泌尿系统。嗜碱细胞数减少、甲床出血、肿瘤破裂、阴道瘘既是新的ADE信号，也是信号强度排前10位的ADE信号。结论培唑帕尼在上市后应用中常见ADE（腹泻、毛发颜色改变、高血压等）的发生情况与其药品说明书基本一致；新的可疑风险信号（嗜碱细胞数减少、甲床出血、肿瘤破裂、阴道瘘等）报道例数较少，还需持续关注。 |
| ABSTRACT： | OBJECTIVE To mine and analyze adverse drug event （ADE） signals after the marketing of pazopanib and provide references for clinically safe medication. METHODS OpenVigil 2.1 data platform was used to mine ADE signals from the US FDA adverse event reporting system （FAERS） database. ADE reports of pazopanib from October 2009 to June 2022 were collected， and ADE signals were analyzed using proportional reporting ratio （PRR） method and reporting odds ratio （ROR） method in the proportional imbalance method. RESULTS A total of 16 655 ADE reports were identified with pazopanib as the primary suspect drug. Through ROR and PRR analysis， 220 ADE signals involving 19 system organ classes were identified. The top 10 ADE signals by frequency were recorded in the drug instruction. Additionally， 88 new ADE signals were discovered， mainly related to the gastrointestinal system， various investigations， and the renal and urinary system. Decreased basophil count， nail bed hemorrhage， tumor rupture， and vaginal fistula were both new ADE signals and the top 10 ADE signals by strength. CONCLUSIONS The occurrence of common ADEs （diarrhea， hair color changes， hypertension， etc.） during the use of pazopanib after marketing is generally consistent with its drug instruction； the number of reported cases for new suspected risk signals （decreased basophil count， nail bed hemorrhage， tumor rupture， and vaginal fistula， etc.） is limited， and continuous monitoring is required. |
| 期刊： | 2023年第34卷第15期 |
| 作者： | 薄明明；石亚飞；孙继雄；王天宇；李国辉；戴媛媛 |
| AUTHORS： | BO Mingming，SHI Yafei，SUN Jixiong，WANG Tianyu，LI Guohui，DAI Yuanyuan |
| 关键字： | 培唑帕尼；药物不良事件；信号挖掘；药物不良反应；比例失衡法 |
| KEYWORDS： | pazopanib； adverse drug event； signal |
| 阅读数： | 272 次 |
| 本月下载数： | 23 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
